Evolution in Theraclion's Capital: Bernard Sabrier & Unigestion Pass the 20% Threshold, Proof of Confidence in the Company's ...
09 Juin 2021 - 06:11PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Memo: ALTHE, PEA-PME
eligible), an innovative company specializing in ultrasound therapy
(using High Intensity Focused Ultrasound or HIFU), announces
that Bernard Sabrier and Unigestion, acting on their own behalf,
have informed Theraclion that they have crossed the thresholds of
20% and 25% of the company's capital and voting rights. This
situation results from the conversion of convertible bonds into
shares and is a sign of confidence in Theraclion's capacity for
innovation and development.
In addition to the provisions of the French Commercial Code and
Theraclion's statutes, Bernard Sabrier's and Unigestion's increase
in Theraclion's share capital comes at a time when the company is
reaching a level of technological maturity with the development of
SONOVEIN S® for the non-invasive treatment of varicose veins, the
rollout of ECHOPULSE® for the treatment of thyroid nodules, and
recent announcement in the treatment of breast cancer, in
partnership with the cancer centre of University of Virginia
(U.S.A.)
The ability to disrupt the world of healthcare.
"I am investing in this company because the technology developed
by Theraclion goes far beyond a simple non-invasive treatment. It
is already disrupting traditional approaches by reducing the burden
on the patient and opening up new therapeutic possibilities.
Ultimately, Theraclion should offer automated, non-invasive,
precise and replicable platforms. Their intelligence and learning
capabilities will continuously improve therapeutic subsequent
procedures. With an upcoming FDA filing process, the current
valuation does not reflect the significant potential of this
company. Theraclion is an example of the best that can be done in
France in terms of medical technology," said Bernard Sabrier, an
international business personality and President of Unigestion, a
specialized investment management company focused on
innovation.
"Bernard Sabrier support us in our technological, commercial and
strategic developments. His confidence in us helps Theraclion to be
more ambitious and innovative in the development of its Echotherapy
platform, which should enable a therapeutic paradigm shift thanks
to this smart, robotic, extra-corporal scalpel," said Caumartin,
CEO of Theraclion.
About Bernard Sabrier
Bernard Sabrier is a Swiss business personality. He is the
Chairman of Unigestion, one of the world's leading asset management
companies, and CEO of Unigestion Asia Pte Ltd. In 1994 Bernard
Sabrier founded Children Action, a charitable foundation for
disadvantaged children around the world. He has just opened an
interactive exhibition Ado-Les-Sens, dedicated to adolescence and
risk in Geneva.
About Theraclion
Theraclion has developed an innovative echotherapy solution
using High Intensity Focused Ultrasound for the treatment of
varicose veins, SONOVEIN®. The treatment solution, which obtained
CE marking in April 2019, is based on the leading-edge echotherapy
treatment expertise developed by Theraclion over years for
non-invasive ablation of breast fibroadenomas and thyroid nodules
using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s office or in clinics, as
well as hospitals. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical devices that are precise and easy to use for
practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210609005712/en/
Theraclion
David Caumartin Chief Executive Officer
david.caumartin@theraclion.com Tel : + 33 (0)1 55 48 90 70
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024